Gentex Corp

for the fiscal year ended December 31 , 2024 or

For the transition period from __________ to _________ Commission File No. : 000-10235 GENTEX CORPORATION (Exact name of registrant as specified in its charter) Michigan 38-2030505 State or other jurisdiction of incorporation or organization (I.R.S. Employer Identification No.) 600 N. Centennial Street, 49464 Zeeland, Michigan (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: 616 - 772-1800

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☑

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). Yes: ☐ No: ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes: ☐ No: ☑

As of June 30, 2024 (the last business day of the registrant's most recently completed second fiscal quarter), 230,229,539 shares of the registrant's common stock, par value $.06 per share, were outstanding. The aggregate market value of the common stock held by non-affiliates of the registrant (i.e., excluding shares held by executive officers, directors, and control persons as defined in Rule 405 (17 CFR 203.405) on that date was $ 7,743,686,144 computed at the closing price on that date.

As of January 31, 2025, 227,195,734 shares of the registrant's common stock, par value $.06 per share, were outstanding, Portions of the Company's Proxy Statement for its 2025 Annual Meeting of Shareholders are incorporated by reference into Part III.

GENTEX CORPORATION AND SUBSIDIARIES For the Year Ended December 31, 2024 FORM 10-K Index

Part I Page Item 1. Business 4 Item 1A. Risk Factors 11 Item 1B. Unresolved Staff Comments 16 Item 1C. Cybersecurity 17 Item 2. Properties 18 Item 3. Legal Proceedings 19 Item 4. Mine Safety Disclosures 19

Part II Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 20 Item 6. Reserved 21 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 27 Item 8. Financial Statements and Supplementary Data 28 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 28 Item 9A. Controls and Procedures 28 Item 9B. Other Information 29 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 29

Part III Item 10. Directors, Executive Officers and Corporate Governance 30 Item 11. Executive Compensation 32 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 36 Item 13. Certain Relationships and Related Transactions, and Director Independence 36 Item 14. Principal Accounting Fees and Services 36

Part IV Item 15. Exhibits, Financial Statement Schedules 37 Item 16. Form 10-K Summary 37